Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | President and CEO | December 22, 2020 | December 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date December 22, 2020 · Filed December 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2030-12-22 | Direct | 125,000 |
Reported balance
After 2020-12-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-22 · Grant · Acquired 125,000 · Balance 125,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2020 Filed Dec 28, 2020 21:30 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock Option · Derivative | 125,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0000899243-20-035197 · doc4.xml · derivative · entry 1 VIRCA NICHOLAS J · CIK 0001284074 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-12-22 Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 22:42 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock Option · Derivative | 100,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0000899243-20-025807 · doc4.xml · derivative · entry 1 VIRCA NICHOLAS J · CIK 0001284074 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-09-17 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 21:00 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Option · Derivative | 310,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0000899243-18-007583 · doc4.xml · derivative · entry 1 VIRCA NICHOLAS J · CIK 0001284074 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2028-03-13 Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:16 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionRestricted Stock Units · Derivative | 15,041,738 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007152 · doc4.xml · derivative · entry 3 VIRCA NICHOLAS J · CIK 0001284074 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,041,738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. F2 · derivative.expiration_date: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:16 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Tax withholdingCommon Stock | 6,314,219 | $0.34 | $2,146,834.46 |
DisclosureSEC source: 0000899243-17-007152 · doc4.xml · nonDerivative · entry 2 VIRCA NICHOLAS J · CIK 0001284074 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,727,519 Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:16 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionCommon Stock | 15,041,738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007152 · doc4.xml · nonDerivative · entry 1 VIRCA NICHOLAS J · CIK 0001284074 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,041,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.